Top Markets
#1 Islamic Coin Islamic Coin +154.33%
#2 PulseChain PulseChain +49.10%
#3 BOOK OF MEME BOOK OF MEME +41.79%
#4 DogBull DogBull +34.87%
#5 rsERG rsERG +21.49%
#6 Ergo Ergo +18.86%
#7 Bio Protocol Bio Protocol +17.68%
#8 ORDI ORDI +16.80%
#9 RedStone RedStone +15.29%
#10 Nockchain Nockchain +15.20%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Mural Oncology plc Mural Oncology plc

Mural Oncology plc

MURA
Rank in Stocks #27070
Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and... Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and advancing immune-based therapies for individuals battling cancer. Its primary drug candidate, nemvaleukin alfa, is currently under investigation as a standalone agent for mucosal melanoma and in partnership with pembrolizumab for platinum-resistant ovarian cancer. Additionally, the company is progressing projects centered on modified interleukin-18 and tumor-specific interleukin-12. Incorporated in 2017, Mural Oncology maintains its headquarters in Dublin, Ireland. By November 15, 2023, the company had transitioned from being a subsidiary of Alkermes plc.
Share Price
$2.04
Last synced: 2025-12-09
Market Cap
$35.38M
Change (1 day)
0.00%
Change (1 year)
-2.39%
Country
IE
Trade Mural Oncology plc (MURA)

Category

Healthcare
Revenue for Mural Oncology plc (MURA)
Revenue in Aug 2026 TTM: 0
According to Mural Oncology plc latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Mural Oncology plc from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH